JP2022549218A5 - - Google Patents

Info

Publication number
JP2022549218A5
JP2022549218A5 JP2022517860A JP2022517860A JP2022549218A5 JP 2022549218 A5 JP2022549218 A5 JP 2022549218A5 JP 2022517860 A JP2022517860 A JP 2022517860A JP 2022517860 A JP2022517860 A JP 2022517860A JP 2022549218 A5 JP2022549218 A5 JP 2022549218A5
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
pharmaceutical composition
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549218A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051416 external-priority patent/WO2021055694A1/en
Publication of JP2022549218A publication Critical patent/JP2022549218A/ja
Publication of JP2022549218A5 publication Critical patent/JP2022549218A5/ja
Pending legal-status Critical Current

Links

JP2022517860A 2019-09-20 2020-09-18 抗トリプターゼ抗体の投薬 Pending JP2022549218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962903409P 2019-09-20 2019-09-20
US62/903,409 2019-09-20
PCT/US2020/051416 WO2021055694A1 (en) 2019-09-20 2020-09-18 Dosing for anti-tryptase antibodies

Publications (2)

Publication Number Publication Date
JP2022549218A JP2022549218A (ja) 2022-11-24
JP2022549218A5 true JP2022549218A5 (cg-RX-API-DMAC7.html) 2023-09-27

Family

ID=72709880

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517860A Pending JP2022549218A (ja) 2019-09-20 2020-09-18 抗トリプターゼ抗体の投薬

Country Status (12)

Country Link
US (1) US20220348687A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031580A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022549218A (cg-RX-API-DMAC7.html)
KR (1) KR20220066295A (cg-RX-API-DMAC7.html)
CN (1) CN114423454A (cg-RX-API-DMAC7.html)
AU (1) AU2020348393A1 (cg-RX-API-DMAC7.html)
CA (1) CA3147179A1 (cg-RX-API-DMAC7.html)
CR (1) CR20220149A (cg-RX-API-DMAC7.html)
IL (1) IL291432A (cg-RX-API-DMAC7.html)
MX (1) MX2022003266A (cg-RX-API-DMAC7.html)
TW (1) TW202126699A (cg-RX-API-DMAC7.html)
WO (1) WO2021055694A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117897409A (zh) * 2021-08-13 2024-04-16 基因泰克公司 抗类胰蛋白酶抗体的给药
CN121693517A (zh) * 2023-04-14 2026-03-17 泰维尼生物公司 双重抑制剂胰蛋白酶抗体以及其用途

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
JP2003516755A (ja) 1999-12-15 2003-05-20 ジェネンテック・インコーポレーテッド ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
KR20050000380A (ko) 2002-04-09 2005-01-03 교와 핫꼬 고교 가부시끼가이샤 게놈이 개변된 세포
WO2003085102A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
CN116715775A (zh) * 2017-02-10 2023-09-08 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途
KR20220098056A (ko) * 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법

Similar Documents

Publication Publication Date Title
JP2020503260A5 (cg-RX-API-DMAC7.html)
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2023551559A5 (cg-RX-API-DMAC7.html)
JP2021518394A5 (cg-RX-API-DMAC7.html)
JP2015500822A5 (cg-RX-API-DMAC7.html)
JP2022532356A5 (cg-RX-API-DMAC7.html)
JP2023542257A5 (cg-RX-API-DMAC7.html)
JP2023548064A5 (cg-RX-API-DMAC7.html)
JP2023520771A5 (cg-RX-API-DMAC7.html)
JP2023545084A5 (cg-RX-API-DMAC7.html)
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
JP2019532970A5 (cg-RX-API-DMAC7.html)
JP2025512785A5 (cg-RX-API-DMAC7.html)
JP2023510199A5 (cg-RX-API-DMAC7.html)
JP2025501978A5 (cg-RX-API-DMAC7.html)
JP2024540226A5 (cg-RX-API-DMAC7.html)
JP2023500697A5 (cg-RX-API-DMAC7.html)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2023542879A5 (cg-RX-API-DMAC7.html)
CN114450025A (zh) 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症
JP2023500480A5 (cg-RX-API-DMAC7.html)
JP2024521105A5 (cg-RX-API-DMAC7.html)
JP2021518348A5 (cg-RX-API-DMAC7.html)
JP2023531090A5 (cg-RX-API-DMAC7.html)
JP2023546504A5 (cg-RX-API-DMAC7.html)